2023-08-29 16:48:23
Updated Tuesday, August 29, 2023 – 16:48
The donated vaccine is the one designed by researchers Juan García Arriaza and Mariano Esteban against SARS-CoV-2 infection, which prevents the virus from replicating in the lungs and brain.
Researchers Juan García Arriaza and Mariano Esteban, from the CNB-CSIC.CSICSalud The CSIC gives its Covid antibody test to the countries most in need
He Higher Council for Scientific Research (CSIC), a body under the Ministry of Science and Innovation, has made its prototype covid-19 vaccine based on the vaccinia MVA virus as a vector available to developing countries. As reported by the CSIC, it is the second agreement signed with the public health organization Medicines Patent Pool (MPP)backed by the United Nations (UN), and under the supervision of the world health organization (WHO) “that will make it easier for this technology to advance to clinical trials and reach the countries most in need.” is the second time that the CSIC cedes a technology through la iniciativa Covid-19 Technology Access Pool (C-TAP) of the WHO to facilitate equal access to health technologies against covid-19.
Included in the agreement are plant visits and training, direct assistance and ongoing consultation with recipient manufacturers, including on quality and regulatory issues. The president of the CSIC, Elosa del Pino, has indicated that “the possibility of finding partners in third countries to advance clinical trials with this vaccine as a future alternative to covid vaccine options licensed worldwide, especially in low-income countries.”
to know ms
Health.
Mariano Esteban’s vaccine at the CSIC desists from carrying out the clinical trial and will focus on new variants
Writing: RRG-A. / AGENCIES Madrid Mariano Esteban’s vaccine at the CSIC desists from carrying out the clinical trial and will focus on new variants
The CSIC will not collect royalties for the exploitation of its vaccine as long as it is manufactured for countries included in the list of those with low or medium income. Del Pino added that “the WHO and MPP Covid-19 Technology Access Pool initiative is an ideal framework for facilitate the transfer of knowledge to those with fewer resources“.
The Council explains that the vaccine is based on the modified Ankara vaccinia virus (MVA) vector expressing the spike (S) protein of SARS-CoV-2 stabilized in prefusion. The prototype has been developed by the team of researchers Mariano Esteban and Juan García Arriaza, from the National Center for Biotechnology (CNB) of the CSIC, also belonging to the CSIC Global Health Interdisciplinary Thematic Platform, which has been financed by the European Recovery Funds.
animal model
The development of its industrial production under quality standards, as detailed by the CSIC, has been carried out through the collaboration of the Council with the Spanish company Biofabri. “Studies carried out in various animal models demonstrate in detail that the MVA-CoV2-S (3P) vaccine activates the immune system and protects against infection by the SARS-CoV-2 coronavirus.”
On the one hand, the vaccine activates an immune response of CD4 T and CD8 T cells against SARS-CoV-2, which is robust, comprehensive, high-quality, and durable. On the other hand, the vaccine induces high levels of IgG binding antibodies against protein S and the receptor-binding domain (RBD) of SARS-CoV-2, as well as neutralizing antibodies against the parental Wuhan variant or against different variants of the virus, which are also durable. “Importantly, the vaccine protects against SARS-CoV-2 infection, preventing virus replication in both the lung and brain, as well as associated pathology (lung and brain damage, and absence of brain storm). cytokines, among other parameters).In addition, in the mouse model, the vaccine prevents mortality caused by SARS-CoV-2“, they explain from CSIC.
Other agreements
In addition to the agreement with the CSIC, the WHO has also reached another with Medigen Vaccine Biologics Corpwhat offers his patent and know-how for a covid-19 vaccine of which have been administered more than three million doses in seven countries. As reported by the WHO, this is the first time that a vaccine manufacturer has used the WHO C-TAP model, “a win-win opportunity for the manufacturer, the recipients of the technology and, most importantly, the users.” patients in need from all over the world“. The agreement will allow the granting of intellectual property licenses facilitating the transfer of technology and the training of personnel.
Thirdly, and within the same package of agreements, the University of Chile is sharing its technology for a Covid-19 assay for the quantification of neutralizing antibodies.
“Covid-19 is here to stay and the world will continue to need tools to prevent, test for and treat it,” said WHO Director-General Tedros Adhanom Ghebreyesus. “Through C-TAP, WHO and its partners have committed to putting those tools available to everyone, everywhere”, he added, and thanked “the leadership” shown by the licensees who have contributed technology.
C-TAP went live in May 2020 hand in hand with the WHO and the Government of Costa Rica with the support of 44 Member States, the United Nations Development Programme, Unitaid, UNAIDS and implementing partners such as the MPP. It was devised to serve as a platform where developers of Covid-19 therapeutics, diagnostics, vaccines and other healthcare products compartan voluntariamente su propiedad intelectualeinsights and data to accelerate technological innovation and expand global production capacity.
#CSIC #transfers #advances #development #Covid19 #vaccine #reaches #developing #countries